Patient No |
De novo tumor |
Liver disease |
Sex |
IMS |
Time from OLT to malignancy (months) |
Treatment |
Outcome |
Post-Tumor
Follow-Up
(months) |
1 |
Esophagus |
ALD |
f |
CyA |
57 |
surgery |
alive nf |
122 |
2 |
Esophagus |
ALD |
m |
CyA |
49 |
rt+ cht + palliation |
died nr |
13 |
3 |
Esophagus |
ALD |
m |
CyA |
84 |
surgery + rt + cht |
alive nf |
83 |
4 |
Esophagus |
ALD |
m |
FK |
66 |
palliation |
died nr |
5 |
5 |
Esophagus |
ALD |
m |
CyA |
45 |
palliation |
died nr |
15 |
6 |
Neck |
ALD |
m |
CyA |
146 |
surgery |
alive nf |
18 |
7 |
Larynx |
ALD |
f |
CyA |
6 |
surgery + rt |
died nr |
139 |
8 |
Salivary gland |
ALD |
m |
CyA |
2 |
surgery + rt |
alive nf |
132 |
9 |
Larynx |
HCV/HBV |
m |
CyA |
98 |
palliation |
died nr |
7 |
10 |
Tongue |
ALD |
m |
CyA |
19 |
surgery |
died nr |
5 |
11 |
Tongue |
ALD |
m |
FK |
13 |
surgery + rt |
alive nf |
99 |
12 |
Pharyngeal |
ALD |
f |
CyA |
131 |
palliation |
died nr |
1 |
13 |
Stomach |
ALD |
m |
CyA |
49 |
surgery |
died nr |
4 |
14 |
Stomach |
HBV |
m |
FK |
77 |
surgery + rt + cht |
alive nf |
39 |
15 |
Stomach |
ALD |
m |
FK |
53 |
surgery |
died nr |
1 |
16 |
Lung |
HCV/HBV |
m |
CyA |
133 |
surgery |
died nr |
3 |
17 |
Lung |
PLD |
m |
FK |
13 |
rt+cht |
died nr |
2 |
18 |
Lung |
PSC |
m |
FK |
34 |
cht |
died nr |
29 |
19 |
Lung |
ALD |
m |
FK |
21 |
cht |
died nr |
10 |
20 |
Colon |
HBV |
m |
CyA |
159 |
surgery |
died nr |
10 |
21 |
Colon |
PSC-HCV |
m |
CyA |
133 |
surgery + cht |
alive nf |
30 |
22 |
Melanoma |
ALD |
m |
CyA |
97 |
surgery |
alive nf |
20 |
23 |
Melanoma |
HCV/HBV |
f |
FK |
15 |
surgery + ifn |
alive nf |
71 |
24 |
Cervix |
ALD |
f |
CyA |
84 |
surgery+rt |
alive nf |
84 |
25 |
Cervix |
HCV |
f |
CyA |
11 |
surgery |
died nr |
16 |
26 |
Breast |
PBC |
f |
FK |
13 |
surgery |
alive nf |
94 |
27 |
Kaposi |
hbv-hdv |
m |
CyA |
13 |
surgery |
died nr |
54 |
28 |
Kaposi |
hbv |
m |
FK |
36 |
surgery |
died nr |
93 |
29 |
Kaposi |
hbv |
m |
FK |
133 |
surgery |
alive nf |
7 |
30 |
Kaposi |
SSC |
m |
CyA |
56 |
surgery |
died nr |
40 |
31 |
Kaposi |
ALD |
m |
CyA |
5 |
reduction IMS |
alive wn |
108 |
32 |
Kaposi |
hcv |
f |
FK |
3 |
surgery |
alive nf |
94 |
33 |
PTLD |
hbv |
m |
CyA |
72 |
surgery cht |
died nr |
64 |
34 |
PTLD |
PSC-hcv |
f |
CyA |
66 |
surgery cht |
died nr |
13 |
35 |
PTLD |
hcv |
m |
FK |
36 |
cht |
alive nf |
32 |
36 |
PTLD |
HCV-HBV |
m |
FK |
58 |
cht+rt |
alive nf |
44 |
37 |
PTLD |
HCV |
m |
FK |
101 |
cht |
died nr |
3 |
38 |
PTLD |
HBV |
m |
CyA |
12 |
cht+rituximab |
alive nf |
24 |
39 |
PTLD |
HCV |
f |
FK |
106 |
cht |
alive nf |
16 |
40 |
PTLD |
HCV |
m |
FK |
80 |
palliation |
died nr |
0 |
|
ALD: Alcoholic Liver Disease; PSC: Primary Sclerosing Cholangitis; PBC: Primary Biliary Cirrhosis; PLD: Polycystic Liver Disease; SSC: Secondary Sclerosing Cholangitis;
nf: neoplsia free; nr: neoplasia related; wn: with neoplasia; cht: chemotherapy; rt: radiotherapy; IMS: Immunosuppression; PTLD: Post-Transplant Lymphoproliferative
Disease |
Table 2: Clinical characteristics of the 40 patients with de novo tumor. |